What is Conduit Pharmaceuticals 12-1 Month Momentum %?
12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2025-01-18), Conduit Pharmaceuticals's 12-1 Month Momentum % is -97.45%.
The industry rank for Conduit Pharmaceuticals's 12-1 Month Momentum % or its related term are showing as below:
CDT's 12-1 Month Momentum % is ranked worse than 98.68% of 1443
companies
in the Biotechnology industry
Industry Median: -18.03
vs CDT: -97.45
Competitive Comparison of Conduit Pharmaceuticals's 12-1 Month Momentum %
For the Biotechnology subindustry, Conduit Pharmaceuticals's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Conduit Pharmaceuticals's 12-1 Month Momentum % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Conduit Pharmaceuticals's 12-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Conduit Pharmaceuticals's 12-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Conduit Pharmaceuticals 12-1 Month Momentum % Related Terms
Thank you for viewing the detailed overview of Conduit Pharmaceuticals's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.
Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being, prioritized by leading biopharmaceutical companies in order to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready in autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CDT has been successfully added to your